The first selective alpha-2A adrenergic receptor agonist licensed for the treatment of ADHD in the EU Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission granted Marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results